122 results on '"Shaw, Bronwen E."'
Search Results
2. Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial
3. Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study
4. Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018
5. Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T
6. Unrelated Stem Cell Donor HLA Match Likelihood in the US Registry Incorporating HLA-DPB1 Permissive Mismatching
7. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial
8. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
9. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplant Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation (EBMT), American Society for Transplantation and Cellular Therapy (ASTCT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR)
10. Skeletal Biology and Late Effects Following Allogeneic Transplantation for Pediatric Hematologic Malignancy: A Ptctc and CIBMTR Multicenter Study
11. Analysis of the CIBMTR US Registry Data on Patient Characteristics, Treatment Patterns and Outcomes of Patients Receiving Extracorporeal Photopheresis with or without Ruxolitinib
12. Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
13. Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors
14. Corrigendum to ‘Current Use and Trends in Hematopoietic Cell Transplantation in the United States’ [Transplantation and Cellular Therapy 26/8 (2020) e177-e182]
15. Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]
16. The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials
17. Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues
18. Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes
19. Orca-T Demonstrates Encouraging Overall Survival, Gvhd Reduction, and Tolerability in Patients with Hematologic Malignancies
20. Chronic Kidney Disease Is Common in Survivors of Pediatric Allogeneic Hematopoietic Cell Transplantation: A Pediatric Transplantation and Cellular Therapy Consortium Study
21. Healthcare Utilization Trends Among Older (Age > 60 Years) Hematopoietic Cell Transplant (HCT) Long-Term Survivors
22. Evaluation of Distress Subscales in Relationship with Transplant Characteristics in Elderly (≥60 years) Hematopoietic Cell Transplant (HCT) Survivors
23. Cryopreservation of Allogeneic Hematopoietic Cell Grafts Did Not Adversely Impact Early Post-Transplant Survival during the First Six Months of the COVID-19 Pandemic
24. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year
25. Biobehavioral Research and Hematopoietic Stem Cell Transplantation: Expert Review from the Biobehavioral Research Special Interest Group of the American Society for Transplantation and Cellular Therapy
26. Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations
27. The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic
28. Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study
29. COVID-19 in Hematopoietic Cell Transplant Recipients: A CIBMTR Study
30. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
31. Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation
32. Orca-T, a Precision Treg-Engineered Donor Product, in Myeloablative HLA-Matched Transplantation Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience
33. Likelihood of Proceeding to Allogeneic Hematopoietic Cell Transplantation in the United States after Search Activation in the National Registry: Impact of Patient Age, Disease, and Search Prognosis
34. Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023
35. Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study
36. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation
37. Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score
38. Letter to the Editor Regarding “Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation”
39. Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation
40. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
41. Return-to-Work Guidelines and Programs for Post-Hematopoietic Cell Transplantation Survivors: An Initial Survey
42. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis
43. Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia
44. Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors
45. Clonal Hematopoiesis in Related Allogeneic Transplant Donors: Implications for Screening and Management
46. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes
47. Hematopoietic Cell Transplantation (HCT) Predictions for the Year 2023
48. Role of Race/Ethnicity in Donor Decisions about Unrelated Hematopoietic Progenitor Cell Donation: Exploring Reasons for Higher Attrition among Racial/Ethnic Minorities
49. Hematopoietic Cell Transplantation (HCT) Followed By Solid Organ Transplantation (SOT) and SOT Followed By HCT: A Descriptive Analysis of Patients Undergoing Sequential Transplantation in the United States
50. Feasibility of Centralized Electronic Patient-Reported Outcome (ePRO) Collection By an Outcome Registry, a CIBMTR Study of Patients on the Centers for Medicaid & Medicare Coverage with Evidence Development (CMS CED) Myelodysplasia Protocol
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.